Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02881567

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab — SUSTAIN  

Relapsing-Remitting Multiple Sclerosis (RRMS) Clinical Trial

Official title:
A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)

Clinical Trial Summary

The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched from treatment with natalizumab to daclizumab due to safety concerns. The secondary objectives of this study in this study population are to evaluate the effects of daclizumab on the following: 1) Multiple Sclerosis (MS) relapse activity including the annualized relapse rate (ARR) and the proportion of participants experiencing relapses requiring hospitalization and/or steroid treatment; 2) MS-related outcomes measured using magnetic resonance imaging (MRI); 3) Safety and tolerability in participants previously treated with natalizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02881567
Study type Interventional
Source Biogen
Contact
Status Terminated
Phase Phase 3
Start date April 18, 2017
Completion date September 12, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05177523 - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Withdrawn NCT05172466 - Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab N/A
Completed NCT05304520 - A Study for Tysabri Participant Preference
Completed NCT04115488 - Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® Phase 3
Recruiting NCT06430671 - Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Phase 1/Phase 2
Recruiting NCT05811416 - A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Active, not recruiting NCT03846219 - MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) Phase 2
Completed NCT02587065 - Plegridy Satisfaction Study in Participants Phase 4
Not yet recruiting NCT02568111 - Brimonidine Tartrate for the Treatment of Injection Related Erythema Phase 4
Terminated NCT01633112 - MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone Phase 3
Completed NCT01738347 - Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). Phase 1
Not yet recruiting NCT05245344 - Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study